A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study To Compare Safety and Pharmacokinetic Properties of CJ-30044 and Bepotastine Besilate and To Investigate Food-effect on Pharmacokinetics of CJ-30044 in Healthy Adult Male Volunteers

Inclusion criteria

• Male volunteers in the age between 20 and 45 years old

• BMI(Body Mass Index) in the range of 18.5 to 25kg/m2
• Subject with no history of any significant chronic disease
• Judged to be in good health on the basis of their vital sign, ECG, physical exam and routine laboratory data for this trial by investigators
• Willing to adhere to protocol requirements and sign a informed consent form

Exclusion criteria

• History of clinically significant allergies, including Bepotastine.
• History of clinically significant hepatic, renal, neurology, psychiatric, pulmonary, endocrine, hematologic, cardiovascular disease
• History of surgery except or gastrointestinal disease which might significantly change absorption of medicines
• Subjects considered as unsuitable health on the basis of their vital sign, ECG, physical exam and routine laboratory data for this trial by investigators.
• Clinical laboratory test values are outside the accepted normal range

• AST or ALT >1.25 times to normal range
• Total bilirubin >1.5 times to normal range
• Estimated GFR(Glomerular Filtration Rate) < 80 mL/min/1.73m2
• Clinically significant vital sign

• SBP(Systolic Blood Pressure) ≤ 90 mmHg or SBP ≥ 150 mmHg
• DBP(Diastolic Blood Pressure) ≤ 50 mmHg or DBP ≥ 100 mmHg
• History of drug abuse or positive urine screen for drugs
• History of caffeine, alcohol, smoking abuse

• caffeine > 5 cups/day
• alcohol > 210g/week
• smoking > 10 cigarettes/day
• Special diet known to interfere with the absorption, distribution, metabolism or excretion of drugs (especially, consumption of grapefruit juice) within 7 days prior to drug administration
• Use of prescription only medicine and oriental medicine within the 14 days before dosing or use of non-prescription medicine within the 7 days before dosing
• Participated in a previous clinical trial within 60 days prior to dosing
• Donated blood within 60 days prior to dosing
• Subjects considered as unsuitable based on medical judgement by investigators